Enzyme replacement therapy
Phase 1Small molecule
Idorsia Pharmaceuticals Ltd.Enzyme replacement therapy is one of 21 small molecule programs targeting Fabry Disease. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Fabry Disease
#DrugCompanyPhaseTrials
1Fabrazyme (agalsidase Beta)
SanofiApproved
Venglustat
SanofiPhase 3
Active Comparator
ModernaPhase 3
Agalsidase
SanofiApproved
Farxiga
AstraZenecaPhase 2
Recombinant Alpha-Galactosidase a
AAssistance Publique - Hôpitaux de Paris
Approved
Replagal
TakedaPhase 3
Galafold
AAmicus Therapeutics
Phase 3
Agalsidase Alfa
TakedaPhase 3
Migalastat Hcl
AAmicus Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enzyme replacement therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company